Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
CME Group Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $109.6B | |
|---|---|---|
| Revenue (ttm) | 7B | |
| Net income (ttm) | 4.4B | |
| EPS (ttm) | $12.2 | |
| Shares out | 357.9M | |
| P/E (trailing) | 24.1x | |
| P/E (forward) | 23.5x | |
| Dividend | $11.4 (3.86%) | |
| Volume | 996,802 | |
| Beta | 0.27 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $4.69B | $5.02B | $5.58B | $6.13B | $6.52B | +8.6% |
| Gross profit | $3.85B | $4.27B | $4.75B | $5.28B | $5.61B | +9.9% |
| Operating income | $3.54B | $3.65B | $4.31B | $4.70B | $5.50B | +11.7% |
| Net income | $2.64B | $2.69B | $3.23B | $3.53B | $4.07B | +11.5% |
| EPS (diluted) | $7.29 | $7.40 | $8.86 | $9.67 | $11.16 | +11.2% |
| EBITDA | $3.93B | $4.02B | $4.67B | $5.04B | $5.83B | +10.4% |
| R&D | — | — | — | — | — | — |
| SG&A | $151.7M | $137.4M | $144.4M | $132.7M | $150.5M | -0.2% |
Recent company headlines from major financial publishers.
Prolonged macroeconomic uncertainty, fluctuating interest rates, and geopolitical shifts drive record hedging activity and volume across CME's product suite. The company pushes through pricing increases uninhibited, scaling margins further and driving low-double-digit EPS growth.
CME Group benefits from near-monopoly network effects in interest rate, energy, and agricultural derivatives. Its vertically integrated clearinghouse acts as a massive competitive barrier. As a mature compounder, it generates extraordinary margins and massive free cash flow.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 7.1% | $313 | $347 | $389 | $444 | $457 |
| 8.1% | $261 | $285 | $313 | $347 | $389 |
| 9.1% | $224 | $241 | $261 | $285 | $313 |
| 10.1% | $196 | $209 | $224 | $241 | $261 |
| 11.1% | $175 | $185 | $196 | $209 | $224 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
